Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.

TSX:TRIL - Post Discussion

Trillium Therapeutics Inc. > The "TRIL" is NOT gone!
View:
Post by SouthernTierTom on Nov 18, 2020 10:04am

The "TRIL" is NOT gone!

Wowzers...........

approaching an 80 BAGGER!!

Congrats to longs and "waht-have-you" ; - )
Comment by SouthernTierTom on Nov 19, 2020 7:46am
WOW!! ...... you fellas make a "pretty darn good case"  Sure the revenue is only 115K for the first nine months, but the loss is only about 173M USD...I guess that would check in at only about 235M CAD.  These biotechs just work this way. As one of my favorite US analysts once said, "never a smooth ride, whilst you carve a new path" Nice thing here is this group ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities